{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:22:51Z","timestamp":1788967371079,"version":"build-2803163510"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n \n No oral medication is currently approved for the management of urolithiasis. Guang Jing Qian Cao (\n Desmodium styracifolium<\/jats:italic>\n total flavone capsules; hereinafter,\n Guang Jing<\/jats:italic>\n ), a traditional Chinese herbal extract, has shown clinical benefits for urolithiasis, but randomized clinical trials are needed to assess its effectiveness.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate whether Guang Jing improves stone passage rates (SPRs) compared with placebo in adults with urolithiasis.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This double-blind, placebo-controlled, phase 3 randomized clinical trial was conducted at 34 sites in China from December 2017 to April 2020. Participants included adults (aged 18-70 years) with diagnosed ureteral stones. Data analysis was conducted on November 4, 2020.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Participants were randomized 3:1 to receive oral Guang Jing (0.6 g) or matching placebo 3 times daily for 28 days, in addition to investigator-prescribed background medication.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n The primary outcome was SPR by day 28, confirmed by computed tomography. Secondary outcomes included SPR by day 14, stone migration rate, and stone migration distance. Between-group comparisons were performed using the Cochran-Mantel-Haenszel test for categorical outcomes and\n t<\/jats:italic>\n tests for continuous outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 606 participants were randomly assigned to receive Guang Jing (n\u2009=\u2009458) or placebo (n\u2009=\u2009148). Their mean (SD) age was 43.0 (12.0) years, 474 (78.2%) were male, and the mean (SD) stone size was 0.6 (0.1) cm. The SPR by day 28 was significantly higher for the Guang Jing group compared with the placebo group (204 of 457 [44.6%] vs 50 of 148 [33.8%]; relative risk, 1.32 [95% CI, 1.03-1.69];\n P<\/jats:italic>\n \u2009=\u2009.03), with an absolute risk difference of 10.9 (95% CI, 2.0-19.7) percentage points. No significant between-group differences in SPR by day 14 (Guang Jing vs placebo: 133 [29.1%] vs 33 [22.3%];\n P<\/jats:italic>\n \u2009=\u2009.14) or stone migration distance (mean [SD], 29.5 [51.8] mm vs 29.7 [43.8] mm;\n P<\/jats:italic>\n \u2009=\u2009.11) were observed. Adverse event rates were similar for the Guang Jing and placebo groups (88 [19.3%] vs 27 [18.2%]).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, treatment with Guang Jing significantly increased the expulsion of 5- to 10-mm ureteral stones by day 28, with a favorable safety profile. These findings suggest that Guang Jing may be an additional medical expulsive therapy option for appropriately selected patients.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n Chinese Clinical Trial Registry Identifier:\n ChiCTR-IIR-17013275<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.32874","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:00:41Z","timestamp":1788966041000},"page":"e2632874","source":"Crossref","is-referenced-by-count":0,"title":["Desmodium styracifolium<\/i>\n Total Flavone Capsules for Urolithiasis"],"prefix":"10.1001","volume":"9","author":[{"given":"Dan","family":"Wang","sequence":"first","affiliation":[{"name":"Clinical Research Center, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunxian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaojun","family":"Xue","sequence":"additional","affiliation":[{"name":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"He","sequence":"additional","affiliation":[{"name":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengji","family":"Zhu","sequence":"additional","affiliation":[{"name":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"9","key":"zoi260896r1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00345-017-2008-6","article-title":"Epidemiology of stone disease across the world.","volume":"35","author":"Sorokin","year":"2017","journal-title":"World J Urol"},{"issue":"1","key":"zoi260896r2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/bju.13828","article-title":"Prevalence of kidney stones in China: an ultrasonography based cross-sectional study.","volume":"120","author":"Zeng","year":"2017","journal-title":"BJU Int"},{"issue":"4","key":"zoi260896r3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ajur.2018.08.007","article-title":"Epidemiology of urolithiasis in Asia.","volume":"5","author":"Liu","year":"2018","journal-title":"Asian J Urol"},{"issue":"2","key":"zoi260896r4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.juro.2016.12.135","article-title":"The risk of chronic kidney disease associated with urolithiasis and its urological treatments: a review.","volume":"198","author":"Gambaro","year":"2017","journal-title":"J Urol"},{"issue":"4","key":"zoi260896r5","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.juro.2016.05.090","article-title":"Surgical management of stones: American Urological Association\/Endourological Society guideline, PART I.","volume":"196","author":"Assimos","year":"2016","journal-title":"J Urol"},{"issue":"9991","key":"zoi260896r7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(15)60933-3","article-title":"Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial.","volume":"386","author":"Pickard","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"zoi260896r8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jep.2011.09.053","article-title":"The genus Desmodium (Fabaceae): traditional uses in Chinese medicine, phytochemistry and pharmacology.","volume":"138","author":"Ma","year":"2011","journal-title":"J Ethnopharmacol"},{"issue":"15","key":"zoi260896r9","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1002\/jssc.202200010","article-title":"Comparative pharmacokinetic studies of five C-glycosylflavones in normal and urolithiasis model rats following administration of total flavonoids from Desmodium styracifolium by liquid chromatography-tandem mass spectrometry.","volume":"45","author":"Li","year":"2022","journal-title":"J Sep Sci"},{"issue":"3","key":"zoi260896r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e25058","article-title":"Desmodium styracifolium: botanical and ethnopharmacological insights, phytochemical investigations, and prospects in pharmacology and pharmacotherapy.","volume":"10","author":"Opryshko","year":"2024","journal-title":"Heliyon"},{"issue":"20","key":"zoi260896r11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"zoi260896r12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.7326\/0003-4819-154-4-201102150-00016","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.","volume":"154","author":"Bian","year":"2011","journal-title":"Ann Intern Med"},{"issue":"8","key":"zoi260896r15","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/jamainternmed.2018.2259","article-title":"Effect of tamsulosin on passage of symptomatic ureteral stones: a randomized clinical trial.","volume":"178","author":"Meltzer","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"3","key":"zoi260896r16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.eururo.2017.10.033","article-title":"Efficacy and safety of tamsulosin in medical expulsive therapy for distal ureteral stones with renal colic: a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"73","author":"Ye","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"zoi260896r17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008509.pub3","article-title":"Alpha-blockers as medical expulsive therapy for ureteral stones.","volume":"4","author":"Campschroer","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"zoi260896r19","article-title":"Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults.","volume":"11","author":"Oestreich","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi260896r20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ijsu.2020.06.025","article-title":"Optimal management of large proximal ureteral stones (>10 mm): a systematic review and meta-analysis of 12 randomized controlled trials.","volume":"80","author":"Lai","year":"2020","journal-title":"Int J Surg"},{"key":"zoi260896r21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1351312","article-title":"Pooled-analysis of tadalafil and tamsulosin for ureteral calculi.","volume":"15","author":"Sun","year":"2024","journal-title":"Front Pharmacol"},{"issue":"3","key":"zoi260896r22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00240-017-0985-y","article-title":"Total flavonoids of Desmodium styracifolium attenuates the formation of hydroxy-L-proline-induced calcium oxalate urolithiasis in rats.","volume":"46","author":"Zhou","year":"2018","journal-title":"Urolithiasis"},{"key":"zoi260896r6","year":"2025"},{"key":"zoi260896r18","author":"Astellas Pharma China, Inc","year":"2020"},{"key":"zoi260896r13","unstructured":"Medical Dictionary for Regulatory Activities (MedRA), version 23.0. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Accessed July 31, 2026. https:\/\/www.meddra.org"},{"key":"zoi260896r14","unstructured":"Anatomical Therapeutic Chemical (ATC) classification system. World Health Organization. Accessed July 31, 2026. https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2853853\/wang_2026_oi_260896_1788273408.59309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:00:43Z","timestamp":1788966043000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2853853"}},"subtitle":["A Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.32874","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}